Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Equity Ratio: 2017-2025

Historic Equity Ratio for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Sep 2025 value amounting to 0.90.

  • Crinetics Pharmaceuticals' Equity Ratio rose 0.88% to 0.90 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.90, marking a year-over-year increase of 0.88%. This contributed to the annual value of 0.92 for FY2024, which is 8.83% up from last year.
  • Per Crinetics Pharmaceuticals' latest filing, its Equity Ratio stood at 0.90 for Q3 2025, which was down 1.32% from 0.91 recorded in Q2 2025.
  • Crinetics Pharmaceuticals' 5-year Equity Ratio high stood at 0.95 for Q4 2021, and its period low was 0.85 during Q4 2023.
  • Its 3-year average for Equity Ratio is 0.89, with a median of 0.89 in 2023.
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' Equity Ratio decreased by 6.48% in 2023, and later increased by 8.83% in 2024.
  • Quarterly analysis of 5 years shows Crinetics Pharmaceuticals' Equity Ratio stood at 0.95 in 2021, then dropped by 5.02% to 0.90 in 2022, then decreased by 5.53% to 0.85 in 2023, then rose by 8.83% to 0.92 in 2024, then increased by 0.88% to 0.90 in 2025.
  • Its Equity Ratio stands at 0.90 for Q3 2025, versus 0.91 for Q2 2025 and 0.92 for Q1 2025.